Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* idiopathic, familial or associated PAH, WHO group 1~* NYHA class II or III~* clinically stable with optimized PAH treatment for at least 3 months~* no or minimal evidence of fluid overload or volume depletion, with or without diuretic treatment~* age \> 18 years~* mean pulmonary artery pressure (mPAP) \> 25 mmHg~* 6 minute walk distance (6MWD) over 100m~Exclusion Criteria:~* Structural heart disease unrelated to PAH~* Recent (\<3 months) treatment with an intravenous positive inotropic agent~* current use of β-blockers~* history of reactive airways disease~* history of adverse reaction to β-blockers~* heart block on ECG or resting heart rate \< 60 bpm~* cardiac index \< 1.8 l/min/m2~* systemic hypotension (systolic pressure \< 90 mmHg)~* pulmonary capillary wedge pressure \> 15 mmHg~* inability to give informed consent~* contraindications to CT and/or PET scanning~* coagulopathy (INR\>1.5 or platelet count\<50000/mm3)~* severe renal insufficiency (creatinine clearance \<30 ml/min/m2)~* malignancy or any co-morbidity limiting survival or conditions predicting inability to complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- carvedilol (Type: EXPERIMENTAL): Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).